(MedPage Today) — SAN FRANCISCO — Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease control with a novel KRAS G12D inhibitor, a small preliminary study showed.
The early results showed that…
Source link : https://www.medpagetoday.com/meetingcoverage/mgics/119372
Author :
Publish date : 2026-01-10 14:01:00
Copyright for syndicated content belongs to the linked Source.
